Dr. Reddy's Laboratories (NYSE: RDY) reported earnings on Oct. 30. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended Sep. 30 (Q2), Dr. Reddy's Laboratories beat expectations on revenues and crushed expectations on earnings per share.

Compared to the prior-year quarter, revenue grew significantly and GAAP earnings per share grew significantly.

Gross margins shrank, operating margins grew, net margins expanded.

Revenue details
 Dr. Reddy's Laboratories booked revenue of $545.0 million. The six analysts polled by S&P Capital IQ hoped for a top line of $522.6 million on the same basis. GAAP reported sales were 18% higher than the prior-year quarter's $462.1 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.55. The one earnings estimate compiled by S&P Capital IQ forecast $0.45 per share. GAAP EPS of $0.45 for Q2 were 22% higher than the prior-year quarter's $0.37 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 53.1%, 70 basis points worse than the prior-year quarter. Operating margin was 20.6%, 410 basis points better than the prior-year quarter. Net margin was 14.1%, 50 basis points better than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $543.9 million. On the bottom line, the average EPS estimate is $0.52.

Next year's average estimate for revenue is $2.10 billion. The average EPS estimate is $1.88.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 496 members out of 522 rating the stock outperform, and 26 members rating it underperform. Among 110 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 107 give Dr. Reddy's Laboratories a green thumbs-up, and three give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Dr. Reddy's Laboratories is outperform, with an average price target of $34.67.